Gland Pharma soars on getting EIR from USFDA for Visakhapatnam facility

24 Jun 2025 Evaluate

Gland Pharma is currently trading at Rs. 1780.00, up by 36.20 points or 2.08% from its previous closing of Rs. 1743.80 on the BSE.

The scrip opened at Rs. 1587.55 and has touched a high and low of Rs. 1800.00 and Rs. 1587.55 respectively. So far 3074 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2220.95 on 06-Aug-2024 and a 52 week low of Rs. 1200.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1800.00 and Rs. 1587.55 respectively. The current market cap of the company is Rs. 29303.58 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 40.17% and 7.99% respectively.

Gland Pharma has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) indicating closure of Pre-approval inspection (PAI) for Sterile APIs at JNPC, Visakhapatnam facility. The said inspection was conducted between February 19, 2025 and February 25, 2025.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1750.55 19.70 (1.14%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×